FDA asks for changes in safety strategy before Ultomiris approval
The U.S. Food and Drug Administration (FDA) has asked for modifications to the risk evaluation and mitigation strategy — known as REMS — for Ultomiris (ravulizumab) before approving the therapy for most adults with neuromyelitis optica spectrum disorder (NMOSD). Ultomiris already is available in the U.S. for treating…